N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor.
Allosteric kinase inhibitors hold promise for revealing unique features of kinases that may not be apparent using conventional ATP-competitive inhibitors. Here we explore the activity of a previously reported allosteric inhibitor of BCR-Abl kinase, GNF-2, against two cellular isoforms of Abl tyrosine kinase: one that carries a myristate in the N terminus and the other that is deficient in N-myristoylation. Our results show that GNF-2 inhibits the kinase activity of non-myristoylated c-Abl more potently than that of myristoylated c-Abl by binding to the myristate-binding pocket in the C-lobe of the kinase domain. Unexpectedly, indirect immunofluorescence reveals a translocation of myristoylated c-Abl to the endoplasmic reticulum in GNF-2-treated cells, whereas GNF-2 has no detectable effect on the localization of non-myristoylated c-Abl. These results indicate that GNF-2 competes with the NH(2)-terminal myristate for binding to the c-Abl kinase myristate-binding pocket and that the exposed myristoyl group accounts for the localization to the endoplasmic reticulum. We also demonstrate that GNF-2 can inhibit enzymatic and cellular kinase activity of Arg, a kinase highly homologous to c-Abl, which is also likely to be regulated through intramolecular binding of an NH(2)-terminal myristate lipid. These results suggest that non-ATP-competitive inhibitors, such as GNF-2, can serve as chemical tools that can discriminate between c-Abl isoform-specific behaviors.
Choi
Yongmun
Y
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Seeliger
Markus A
MA
Panjarian
Shoghag B
SB
Kim
Hakjoong
H
Deng
Xianming
X
Sim
Taebo
T
Couch
Brian
B
Koleske
Anthony J
AJ
Smithgall
Thomas E
TE
Gray
Nathanael S
NS
D016475:3T3 Cells; D000255:Adenosine Triphosphate / Q000737:chemistry; D000495:Allosteric Site; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001665:Binding Sites; D019008:Drug Resistance, Neoplasm; D004721:Endoplasmic Reticulum / Q000201:enzymology*; D006801:Humans; D008055:Lipids / Q000737:chemistry; D051379:Mice; D008968:Molecular Conformation; D020033:Protein Isoforms; D017434:Protein Structure, Tertiary; D016315:Proto-Oncogene Proteins c-abl / Q000378:metabolism / Q000502:physiology*
D000970:Antineoplastic Agents; D008055:Lipids; D020033:Protein Isoforms; D000255:Adenosine Triphosphate; D016315:Proto-Oncogene Proteins c-abl
Structure. 2005 Jun;13(6):861-71
15939018
Nature. 1995 Feb 9;373(6514):536-9
7845468
J Cell Biol. 1998 May 18;141(4):887-94
9585408
Genes Dev. 1997 Oct 1;11(19):2456-67
9334312
J Mol Biol. 2008 Jan 4;375(1):70-9
17999933
Oncogene. 2008 Jul 24;27(32):4385-91
18391983
Nat Biotechnol. 2008 Jan;26(1):127-32
18183025
Nat Chem Biol. 2008 Aug;4(8):474-82
18641628
Neuron. 1998 Dec;21(6):1259-72
9883720
Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17456-61
15505216
Nat Cell Biol. 2004 Jan;6(1):3-7
14704671
Cell. 2003 Mar 21;112(6):859-71
12654251
J Biol Chem. 2001 Jul 20;276(29):27104-10
11309382
Anal Biochem. 2009 Feb 15;385(2):300-8
19059193
Nat Chem Biol. 2006 Feb;2(2):95-102
16415863
Oncogene. 2007 Oct 25;26(49):6989-96
17486070
J Cell Biol. 2004 May 10;165(3):407-19
15138293
Oncogene. 2007 Nov 15;26(52):7313-23
17533370
Adv Cancer Res. 2002;85:51-100
12374288
J Cell Sci. 2003 Jul 1;116(Pt 13):2613-26
12775773
Nat Rev Cancer. 2007 May;7(5):345-56
17457302
Cell. 2003 Mar 21;112(6):845-57
12654250
Oncogene. 2008 Feb 14;27(8):1095-105
17700528
Biochemistry. 1995 Nov 14;34(45):14843-51
7578094
Mol Cell Biol. 2001 Sep;21(18):6233-42
11509666
Cell. 1993 Nov 19;75(4):615-30
8242738
Proc Natl Acad Sci U S A. 1990 Aug;87(15):5802-6
2198571
J Biol Chem. 1985 Jul 5;260(13):8070-7
2989275
Protein Sci. 2005 Dec;14(12):3135-9
16260764
Mol Cell. 2006 Mar 17;21(6):787-98
16543148
Nat Rev Mol Cell Biol. 2004 Jan;5(1):33-44
14708008